Valeant CEO Pledges to Heed Critics After ‘Painful’ Experience

Updated on
  • Dermatology business to be hurt by Philidor shutdown
  • Shares slide in early trading after two days of gains

Striking a more reflective tone and pledging to listen to critics, Valeant Pharmaceuticals International Inc. Chief Executive Officer Mike Pearson sought to regain confidence from investors in remarks that painted a fuller picture of the drugmaker’s financial exposure to a controversial pharmacy partner.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.